Bright minds biosciences to host virtual r&d day on may 20, 2025; program highlights include an overview of absence seizures and the bmb-101 phase 2 study

Vancouver, british columbia, april 28, 2025 (globe newswire) -- bright minds biosciences inc. (cse: drug) (nasdaq: drug) (“bright minds” or the “company”), a company focused on developing highly selective 5-ht2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (cns) disorders, today announced that it will host a virtual r&d day on tuesday, may 20, 2025, from 10:00 am – 11:30 am et.
DRUG Ratings Summary
DRUG Quant Ranking